I'm LongbridgeAI, I can summarize articles.ARS Pharmaceuticals announced that Director Richard Lowenthal resigned and Chief Medical Officer Sarina Tanimoto departed, both effective July 15, 2026. The changes involve severance packages and prorated 2026 bonuses for both executives, conditioned on the effectiveness of release agreements. These details were disclosed in an SEC 8-K filing dated July 17, 2026.
ARS Pharmaceuticals saw director Richard Lowenthal resign from the board and Chief Medical Officer Sarina Tanimoto leave the company, both effective July 15, 2026, with severance and prorated bonus payments agreed.
| Individual | Richard Lowenthal | Sarina Tanimoto, M.D. |
| Role | Member of the Board of Directors | Chief Medical Officer |
| Type of Change | Resigned | Terminated without cause / Ceased employment |
| Effective Date | July 15, 2026 | July 15, 2026 |
| Reason | Resignation was a condition to receive severance under his employment agreement and the Company's Change in Control and Severance Benefit Plan | Termination without cause |
| Replacement Info | Not disclosed | Not disclosed |
| Background Details | Referenced employment agreement and Change in Control and Severance Benefit Plan per Proxy Statement dated April 29, 2026 | Served as Chief Medical Officer (no additional background disclosed) |
| Board/Committee Role Changes | Not disclosed | Not disclosed |
| Severance / Additional Payment | Severance per Proxy Statement plus one-time prorated 2026 bonus payment of $217,350, conditioned on release effectiveness | Severance per Proxy Statement plus one-time prorated 2026 bonus payment of $111,780, conditioned on release effectiveness |
Original SEC Filing: ARS Pharmaceuticals, Inc. [ SPRY ] - 8-K - Jul. 17, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.